|
1
|
Storch J and Corsico B: The
multifunctional family of mammalian fatty Acid-binding proteins.
Annu Rev Nutr. 43:25–54. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Corsico B, Cistola DP, Frieden C and
Storch J: The helical domain of intestinal fatty acid binding
protein is critical for collisional transfer of fatty acids to
phospholipid membranes. Proc Natl Acad Sci USA. 95:12174–12178.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hotamisligil GS and Bernlohr DA: Metabolic
functions of FABPs-mechanisms and therapeutic implications. Nat Rev
Endocrinol. 11:592–605. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Storch J and Thumser AE: Tissue-specific
functions in the fatty acid-binding protein family. J Biol Chem.
285:32679–32683. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prentice KJ, Saksi J and Hotamisligil GS:
Adipokine FABP4 integrates energy stores and counterregulatory
metabolic responses. J Lipid Res. 60:734–740. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hotamisligil GS: Inflammation and
metabolic disorders. Nature. 444:860–867. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Furuhashi M, Saitoh S, Shimamoto K and
Miura T: Fatty Acid-binding protein 4 (FABP4): Pathophysiological
insights and potent clinical biomarker of metabolic and
cardiovascular diseases. Clin Med Insights Cardiol. 8:23–33.
2014.
|
|
8
|
Huang X, Liu G, Guo J and Su Z: The
PI3K/AKT pathway in obesity and type 2 diabetes. Int J Biol Sci.
14:1483–1496. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Furuhashi M and Hotamisligil GS: Fatty
acid-binding proteins: Role in metabolic diseases and potential as
drug targets. Nat Rev Drug Discov. 7:489–503. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hotamisligil GS, Johnson RS, Distel RJ,
Ellis R, Papaioannou VE and Spiegelman BM: Uncoupling of obesity
from insulin resistance through a targeted mutation in aP2, the
adipocyte fatty acid binding protein. Science. 274:1377–1379. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Makowski L, Brittingham KC, Reynolds JM,
Suttles J and Hotamisligil GS: The fatty acid-binding protein, aP2,
coordinates macrophage cholesterol trafficking and inflammatory
activity. Macrophage expression of aP2 impacts peroxisome
proliferator-activated receptor gamma and IkappaB kinase
activities. J Biol Chem. 280:12888–12895. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hao J, Zhang Y, Yan X, Yan F, Sun Y, Zeng
J, Waigel S, Yin Y, Fraig MM, Egilmez NK, et al: Circulating
adipose fatty acid binding protein is a new link underlying
Obesity-Associated Breast/Mammary tumor development. Cell Metab.
28:689–705.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
George Warren W, Osborn M, Yates A, Wright
K and O'Sullivan SE: The emerging role of fatty acid binding
protein 5 (FABP5) in cancers. Drug Discov Today. 28:1036282023.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
O'Sullivan SE and Kaczocha M: FABP5 as a
novel molecular target in prostate cancer. Drug Discov Today.
25:2056–2061. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jin R, Hao J, Yu J, Wang P, Sauter ER and
Li B: Role of FABP5 in T cell lipid metabolism and function in the
tumor microenvironment. Cancers (Basel). 15:6572023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye M, Hu C, Chen T, Yu P, Chen J, Lu F, Xu
L, Zhong Y, Yan L, Kan J, et al: FABP5 suppresses colorectal cancer
progression via mTOR-mediated autophagy by decreasing FASN
expression. Int J Biol Sci. 19:3115–3127. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Seo J, Yun J, Fukuda J and Chun YS:
Tumor-intrinsic FABP5 is a novel driver for colon cancer cell
growth via the HIF-1 signaling pathway. Cancer Genet.
258-259:151–156. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guaita-Esteruelas S, Gumà J, Masana L and
Borràs J: The peritumoural adipose tissue microenvironment and
cancer. The roles of fatty acid binding protein 4 and fatty acid
binding protein 5. Mol Cell Endocrinol. 462:107–118. 2018.
View Article : Google Scholar
|
|
19
|
Liu S, Wu D, Fan Z, Yang J, Li Y, Meng Y,
Gao C and Zhan H: FABP4 in obesity-associated carcinogenesis: Novel
insights into mechanisms and therapeutic implications. Front Mol
Biosci. 9:9739552022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chmurzyńska A: The multigene family of
fatty acid-binding proteins (FABPs): Function, structure and
polymorphism. J Appl Genet. 47:39–48. 2006. View Article : Google Scholar
|
|
21
|
Smathers RL and Petersen DR: The human
fatty acid-binding protein family: Evolutionary divergences and
functions. Hum Genomics. 5:170–191. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Veerkamp JH and Maatman RG: Cytoplasmic
fatty acid-binding proteins: Their structure and genes. Prog Lipid
Res. 34:17–52. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zimmerman AW and Veerkamp JH: New insights
into the structure and function of fatty acid-binding proteins.
Cell Mol Life Sci. 59:1096–1116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ockner RK, Manning JA, Poppenhausen RB and
Ho WK: A binding protein for fatty acids in cytosol of intestinal
mucosa, liver, myocardium, and other tissues. Science. 177:56–58.
1972. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Glatz JF and van der Vusse GJ: Cellular
fatty acid-binding proteins: Their function and physiological
significance. Prog Lipid Res. 35:243–282. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hanhoff T, Lücke C and Spener F: Insights
into binding of fatty acids by fatty acid binding proteins. Mol
Cell Biochem. 239:45–54. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu RZ, Li X and Godbout R: A novel fatty
acid-binding protein (FABP) gene resulting from tandem gene
duplication in mammals: Transcription in rat retina and testis.
Genomics. 92:436–445. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haunerland NH and Spener F: Fatty
acid-binding proteins-insights from genetic manipulations. Prog
Lipid Res. 43:328–349. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Y, Zhang J, Ren Y, Lu R, Yang L and
Nie G: Tracing the evolution of fatty acid-binding proteins (FABPs)
in organisms with a heterogeneous fat distribution. FEBS Open Bio.
10:861–872. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Richieri GV, Ogata RT, Zimmerman AW,
Veerkamp JH and Kleinfeld AM: Fatty acid binding proteins from
different tissues show distinct patterns of fatty acid
interactions. Biochemistry. 39:7197–7204. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thompson J, Winter N, Terwey D, Bratt J
and Banaszak L: The crystal structure of the liver fatty
acid-binding protein. A complex with two bound oleates. J Biol
Chem. 272:7140–7150. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hohoff C, Börchers T, Rüstow B, Spener F
and van Tilbeurgh H: Expression, purification, and crystal
structure determination of recombinant human epidermal-type fatty
acid binding protein. Biochemistry. 38:12229–12239. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bennaars-Eiden A, Higgins L, Hertzel AV,
Kapphahn RJ, Ferrington DA and Bernlohr DA: Covalent modification
of epithelial fatty acid-binding protein by 4-hydroxynonenal in
vitro and in vivo. Evidence for a role in antioxidant biology. J
Biol Chem. 277:50693–50702. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu B, Chen L, Zhan Y, Marquez KNS, Zhuo L,
Qi S, Zhu J, He Y, Chen X, Zhang H, et al: The biological functions
and regulatory mechanisms of fatty acid binding protein 5 in
various diseases. Front Cell Dev Biol. 10:8579192022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maeda K, Cao H, Kono K, Gorgun CZ,
Furuhashi M, Uysal KT, Cao Q, Atsumi G, Malone H, Krishnan B, et
al: Adipocyte/macrophage fatty acid binding proteins control
integrated metabolic responses in obesity and diabetes. Cell Metab.
1:107–119. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schug TT, Berry DC, Shaw NS, Travis SN and
Noy N: Opposing effects of retinoic acid on cell growth result from
alternate activation of two different nuclear receptors. Cell.
129:723–733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu RZ, Graham K, Glubrecht DD, Germain
DR, Mackey JR and Godbout R: Association of FABP5 expression with
poor survival in triple-negative breast cancer: Implication for
retinoic acid therapy. Am J Pathol. 178:997–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schug TT, Berry DC, Toshkov IA, Cheng L,
Nikitin AY and Noy N: Overcoming retinoic acid-resistance of
mammary carcinomas by diverting retinoic acid from PPARbeta/delta
to RAR. Proc Natl Acad Sci USA. 105:7546–7551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schroeder F, Petrescu AD, Huang H,
Atshaves BP, McIntosh AL, Martin GG, Hostetler HA, Vespa A,
Landrock D, Landrock KK, et al: Role of fatty acid binding proteins
and long chain fatty acids in modulating nuclear receptors and gene
transcription. Lipids. 43:1–17. 2008. View Article : Google Scholar
|
|
40
|
Tan NS, Shaw NS, Vinckenbosch N, Liu P,
Yasmin R, Desvergne B, Wahli W and Noy N: Selective cooperation
between fatty acid binding proteins and peroxisome
proliferator-activated receptors in regulating transcription. Mol
Cell Biol. 22:5114–5127. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ayers SD, Nedrow KL, Gillilan RE and Noy
N: Continuous nucleocytoplasmic shuttling underlies transcriptional
activation of PPARgamma by FABP4. Biochemistry. 46:6744–6752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Adida A and Spener F: Adipocyte-type fatty
acid-binding protein as inter-compartmental shuttle for peroxisome
proliferator activated receptor gamma agonists in cultured cell.
Biochim Biophys Acta. 1761:172–181. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Garin-Shkolnik T, Rudich A, Hotamisligil
GS and Rubinstein M: FABP4 attenuates PPARγ and adipogenesis and is
inversely correlated with PPARγ in adipose tissues. Diabetes.
63:900–911. 2014. View Article : Google Scholar
|
|
44
|
Hao J, Yan F, Zhang Y, Triplett A, Zhang
Y, Schultz DA, Sun Y, Zeng J, Silverstein KAT, Zheng Q, et al:
Expression of Adipocyte/Macrophage fatty Acid-binding protein in
Tumor-associated macrophages promotes breast cancer progression.
Cancer Res. 78:2343–2355. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hertzel AV and Bernlohr DA: The mammalian
fatty acid-binding protein multigene family: Molecular and genetic
insights into function. Trends Endocrinol Metab. 11:175–180. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Glass CK and Saijo K: Nuclear receptor
transrepression pathways that regulate inflammation in macrophages
and T cells. Nat Rev Immunol. 10:365–376. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tontonoz P and Spiegelman BM: Fat and
beyond: The diverse biology of PPARgamma. Annu Rev Biochem.
77:289–312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Makowski L, Boord JB, Maeda K, Babaev VR,
Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS
and Linton MF: Lack of macrophage fatty-acid-binding protein aP2
protects mice deficient in apolipoprotein E against
atherosclerosis. Nat Med. 7:699–705. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pascual G, Fong AL, Ogawa S, Gamliel A, Li
AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG and Glass CK: A
SUMOylation-dependent pathway mediates transrepression of
inflammatory response genes by PPAR-gamma. Nature. 437:759–763.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cao H, Maeda K, Gorgun CZ, Kim HJ, Park
SY, Shulman GI, Kim JK and Hotamisligil GS: Regulation of metabolic
responses by adipocyte/macrophage Fatty Acid-binding proteins in
leptin-deficient mice. Diabetes. 55:1915–1922. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Furuhashi M, Tuncman G, Görgün CZ,
Makowski L, Atsumi G, Vaillancourt E, Kono K, Babaev VR, Fazio S,
Linton MF, et al: Treatment of diabetes and atherosclerosis by
inhibiting fatty-acid-binding protein aP2. Nature. 447:959–965.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu H, Hertzel AV, Steen KA, Wang Q,
Suttles J and Bernlohr DA: Uncoupling lipid metabolism from
inflammation through fatty acid binding protein-dependent
expression of UCP2. Mol Cell Biol. 35:1055–1065. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Steen KA, Xu H and Bernlohr DA: FABP4/aP2
regulates macrophage redox signaling and inflammasome activation
via control of UCP2. Mol Cell Biol. 37:e00282–16. 2017. View Article : Google Scholar :
|
|
54
|
Xu L, Zhang H, Wang Y, Yang A, Dong X, Gu
L, Liu D, Ding N and Jiang Y: FABP4 activates the JAK2/STAT2
pathway via Rap1a in the homocysteine-induced macrophage
inflammatory response in ApoE(-/-) mice atherosclerosis. Lab
Invest. 102:25–37. 2022. View Article : Google Scholar :
|
|
55
|
Kagawa Y, Low YL, Pyun J, Doglione U,
Short JL, Pan Y and Nicolazzo JA: Fatty Acid-Binding protein 4 is
essential for the inflammatory and metabolic response of microglia
to lipopolysaccharide. J Neuroimmune Pharmacol. 18:448–461. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Erbay E, Babaev VR, Mayers JR, Makowski L,
Charles KN, Snitow ME, Fazio S, Wiest MM, Watkins SM, Linton MF and
Hotamisligil GS: Reducing endoplasmic reticulum stress through a
macrophage lipid chaperone alleviates atherosclerosis. Nat Med.
15:1383–1391. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hoo RL, Shu L, Cheng KK, Wu X, Liao B, Wu
D, Zhou Z and Xu A: Adipocyte fatty acid binding protein
potentiates toxic Lipids-induced endoplasmic reticulum stress in
macrophages via inhibition of janus kinase 2-dependent autophagy.
Sci Rep. 7:406572017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Korbecki J and Bajdak-Rusinek K: The
effect of palmitic acid on inflammatory response in macrophages: An
overview of molecular mechanisms. Inflamm Res. 68:915–932. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Rao E, Singh P, Zhai X, Li Y, Zhu G, Zhang
Y, Hao J, Chi YI, Brown RE, Cleary MP and Li B: Inhibition of tumor
growth by a newly-identified activator for epidermal fatty acid
binding protein. Oncotarget. 6:7815–7827. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kazemi MR, McDonald CM, Shigenaga JK,
Grunfeld C and Feingold KR: Adipocyte fatty acid-binding protein
expression and lipid accumulation are increased during activation
of murine macrophages by toll-like receptor agonists. Arterioscler
Thromb Vasc Biol. 25:1220–1224. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang Y, Sun Y, Rao E, Yan F, Li Q, Zhang
Y, Silverstein KA, Liu S, Sauter E, Cleary MP and Li B: Fatty
acid-binding protein E-FABP restricts tumor growth by promoting
IFN-β responses in tumor-associated macrophages. Cancer Res.
74:2986–2998. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Babaev VR, Runner RP, Fan D, Ding L, Zhang
Y, Tao H, Erbay E, Görgün CZ, Fazio S, Hotamisligil GS and Linton
MF: Macrophage Mal1 deficiency suppresses atherosclerosis in
low-density lipoprotein receptor-null mice by activating peroxisome
proliferator-activated receptor-γ-regulated genes. Arterioscler
Thromb Vasc Biol. 31:1283–1290. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Li B, Reynolds JM, Stout RD, Bernlohr DA
and Suttles J: Regulation of Th17 differentiation by epidermal
fatty acid-binding protein. J Immunol. 182:7625–7633. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Rao E, Singh P, Li Y, Zhang Y, Chi YI,
Suttles J and Li B: Targeting epidermal fatty acid binding protein
for treatment of experimental autoimmune encephalomyelitis. BMC
Immunol. 16:282015. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lee J, Kim B, Chu H, Zhang K, Kim H, Kim
JH, Kim SH, Pan Y, Noh JY, Sun Z, et al: FABP5 as a possible
biomarker in atopic march: FABP5-induced Th17 polarization, both in
mouse model and human samples. EBioMedicine. 58:1028792020.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li B and Schmidt NW: Epidermal fatty acid
binding protein (E-FABP) is not required for the generation or
maintenance of effector and memory T cells following infection with
Listeria monocytogenes. PLoS One. 11:e01624272016. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Field CS, Baixauli F, Kyle RL, Puleston
DJ, Cameron AM, Sanin DE, Hippen KL, Loschi M, Thangavelu G,
Corrado M, et al: Mitochondrial integrity regulated by lipid
metabolism is a Cell-intrinsic checkpoint for treg suppressive
function. Cell Metab. 31:422–437.e5. 2020. View Article : Google Scholar :
|
|
68
|
Wang G, Bonkovsky HL, de Lemos A and
Burczynski FJ: Recent insights into the biological functions of
liver fatty acid binding protein 1. J Lipid Res. 56:2238–2247.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Fang XX, Wei P, Zhao K, Sheng ZC, Song BL,
Yin L and Luo J: Fatty acid-binding proteins 3, 7, and 8 bind
cholesterol and facilitate its egress from lysosomes. J Cell Biol.
223:e2022110622024. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cheng A, Jia W, Kawahata I and Fukunaga K:
Impact of fatty Acid-binding proteins in α-Synuclein-induced
mitochondrial injury in synucleinopathy. Biomedicines. 9:5602021.
View Article : Google Scholar
|
|
71
|
Cao H, Sekiya M, Ertunc ME, Burak MF,
Mayers JR, White A, Inouye K, Rickey LM, Ercal BC, Furuhashi M, et
al: Adipocyte lipid chaperone AP2 is a secreted adipokine
regulating hepatic glucose production. Cell Metab. 17:768–778.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ertunc ME, Sikkeland J, Fenaroli F,
Griffiths G, Daniels MP, Cao H, Saatcioglu F and Hotamisligil GS:
Secretion of fatty acid binding protein aP2 from adipocytes through
a nonclassical pathway in response to adipocyte lipase activity. J
Lipid Res. 56:423–434. 2015. View Article : Google Scholar
|
|
73
|
Villeneuve J, Bassaganyas L, Lepreux S,
Chiritoiu M, Costet P, Ripoche J, Malhotra V and Schekman R:
Unconventional secretion of FABP4 by endosomes and secretory
lysosomes. J Cell Biol. 217:649–665. 2018. View Article : Google Scholar :
|
|
74
|
Wu YW, Chang TT, Chang CC and Chen JW:
Fatty-acid-binding protein 4 as a novel contributor to mononuclear
cell activation and endothelial cell dysfunction in
atherosclerosis. Int J Mol Sci. 21:92452020. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Burak MF, Inouye KE, White A, Lee A,
Tuncman G, Calay ES, Sekiya M, Tirosh A, Eguchi K, Birrane G, et
al: Development of a therapeutic monoclonal antibody that targets
secreted fatty acid-binding protein aP2 to treat type 2 diabetes.
Sci Transl Med. 7:319ra2052015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mukherjee A, Chiang CY, Daifotis HA,
Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O and Lengyel
E: Adipocyte-induced FABP4 expression in ovarian cancer cells
promotes metastasis and mediates carboplatin resistance. Cancer
Res. 80:1748–1761. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Uehara H, Takahashi T, Oha M, Ogawa H and
Izumi K: Exogenous fatty acid binding protein 4 promotes human
prostate cancer cell progression. Int J Cancer. 135:2558–2568.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Lengyel E, Makowski L, DiGiovanni J and
Kolonin MG: Cancer as a matter of fat: The Crosstalk between
adipose tissue and tumors. Trends Cancer. 4:374–384. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Nieman KM, Kenny HA, Penicka CV, Ladanyi
A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB,
Hotamisligil GS, et al: Adipocytes promote ovarian cancer
metastasis and provide energy for rapid tumor growth. Nat Med.
17:1498–1503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Nieman KM, Romero IL, Van Houten B and
Lengyel E: Adipose tissue and adipocytes support tumorigenesis and
metastasis. Biochim Biophys Acta. 1831:1533–1541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ladanyi A, Mukherjee A, Kenny HA, Johnson
A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag
A, et al: Adipocyte-induced CD36 expression drives ovarian cancer
progression and metastasis. Oncogene. 37:2285–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pascual G, Avgustinova A, Mejetta S,
Martín M, Castellanos A, Attolini CS, Berenguer A, Prats N, Toll A,
Hueto JA, et al: Targeting metastasis-initiating cells through the
fatty acid receptor CD36. Nature. 541:41–45. 2017. View Article : Google Scholar
|
|
83
|
Corbet C and Feron O: Emerging roles of
lipid metabolism in cancer progression. Curr Opin Clin Nutr Metab
Care. 20:254–260. 2017.PubMed/NCBI
|
|
84
|
Gyamfi J, Yeo JH, Kwon D, Min BS, Cha YJ,
Koo JS, Jeong J, Lee J and Choi J: Interaction between CD36 and
FABP4 modulates adipocyte-induced fatty acid import and metabolism
in breast cancer. NPJ Breast Cancer. 7:1292021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Mintz RL, Han J, Butka EG, Gallerand A,
Gao S, Kim A, Ning S, Yiew NKH, Wohltmann M, Fedotova G, et al:
Peritoneal ovarian cancer growth in the omentum proceeds
independently of mature adipocytes. Nat Commun. 17:96732026.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Yorek M, Jiang X, Liu S, Hao J, Yu J,
Avellino A, Liu Z, Curry M, Keen H, Shao J, et al: FABP4-mediated
lipid accumulation and lipolysis in tumor-associated macrophages
promote breast cancer metastasis. Elife. 13:RP1012212024.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kannan-Thulasiraman P, Seachrist DD,
Mahabeleshwar GH, Jain MK and Noy N: Fatty acid-binding protein 5
and PPARbeta/delta are critical mediators of epidermal growth
factor receptor-induced carcinoma cell growth. J Biol Chem.
285:19106–19115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Naeem AA, Abdulsamad SA, Zeng H, He G, Jin
X, Zhang J, Alenezi BT, Ma H, Rudland PS and Ke Y: FABP5 can
substitute for androgen receptor in malignant progression of
prostate cancer cells. Int J Oncol. 64:182024. View Article : Google Scholar :
|
|
89
|
Wang W, Chu HJ, Liang YC, Huang JM, Shang
CL, Tan H, Liu D, Zhao YH, Liu TY and Yao SZ: FABP5 correlates with
poor prognosis and promotes tumor cell growth and metastasis in
cervical cancer. Tumour Biol. 37:14873–14883. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zhang C, Liao Y, Liu P, Du Q, Liang Y, Ooi
S, Qin S, He S, Yao S and Wang W: FABP5 promotes lymph node
metastasis in cervical cancer by reprogramming fatty acid
metabolism. Theranostics. 10:6561–6580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Lu F, Ye M, Hu C, Chen J, Yan L, Gu D, Xu
L, Tian Y, Bai J and Tang Q: FABP5 regulates lipid metabolism to
facilitate pancreatic neuroendocrine neoplasms progression via FASN
mediated Wnt/β-catenin pathway. Cancer Sci. 114:3553–3567. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tong J, Han T, Deng J, Gan Y, Ruan R, Zhao
W, Xiong C, Liao Q, Chen S, Bu H, et al: p53 and fatty acids
collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in
colorectal cancer. Redox Biol. 90:1040432026. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Kaczocha M, Rebecchi MJ, Ralph BP, Teng
YH, Berger WT, Galbavy W, Elmes MW, Glaser ST, Wang L, Rizzo RC, et
al: Inhibition of fatty acid binding proteins elevates brain
anandamide levels and produces analgesia. PLoS One. 9:e942002014.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Jin R, Hao J, Yi Y, Yin D, Hua Y, Li X,
Bao H, Han X, Egilmez NK, Sauter ER and Li B: Dietary fats high in
linoleic acids impair antitumor T-cell responses by inducing
E-FABP-Mediated mitochondrial dysfunction. Cancer Res.
81:5296–5310. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Arai Y, Funatsu N, Numayama-Tsuruta K,
Nomura T, Nakamura S and Osumi N: Role of Fabp7, a downstream gene
of Pax6, in the maintenance of neuroepithelial cells during early
embryonic development of the rat cortex. J Neurosci. 25:9752–9761.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Liu RZ, Choi WS, Jain S, Xu X, Elsherbiny
ME, Glubrecht DD, Tessier AG, Easaw JC, Fallone BG and Godbout R:
Stationary-to-migratory transition in glioblastoma stem-like cells
driven by a fatty acid-binding protein 7-RXRα neurogenic pathway.
Neuro Oncol. 25:2177–2190. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Alshareeda AT, Rakha EA, Nolan CC, Ellis
IO and Green AR: Fatty acid binding protein 7 expression and its
sub-cellular localization in breast cancer. Breast Cancer Res
Treat. 134:519–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Morihiro Y, Yasumoto Y, Vaidyan LK,
Sadahiro H, Uchida T, Inamura A, Sharifi K, Ideguchi M, Nomura S,
Tokuda N, et al: Fatty acid binding protein 7 as a marker of glioma
stem cells. Pathol Int. 63:546–553. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
De Rosa A, Pellegatta S, Rossi M, Tunici
P, Magnoni L, Speranza MC, Malusa F, Miragliotta V, Mori E,
Finocchiaro G and Bakker A: A radial glia gene marker, fatty acid
binding protein 7 (FABP7), is involved in proliferation and
invasion of glioblastoma cells. PLoS One. 7:e521132012. View Article : Google Scholar
|
|
100
|
Tsuchiya H and Shiota G: Immune evasion by
cancer stem cells. Regen Ther. 17:20–33. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Choi WS, Xu X, Goruk S, Wang Y, Patel S,
Chow M, Field CJ and Godbout R: FABP7 Facilitates uptake of
docosahexaenoic acid in glioblastoma neural Stem-like cells.
Nutrients. 13:26642021. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Sun Y, Mu G, Xue Z, Wang S, Li X, Ni S and
Han M: Polyunsaturated fatty acid-binding protein FABP7, an
attractive metabolic target for inhibition of glioblastoma stem
cells. Neuro Oncol. 26:587–589. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Ku CY, Liu YH, Lin HY, Lu SC and Lin JY:
Liver fatty acid-binding protein (L-FABP) promotes cellular
angiogenesis and migration in hepatocellular carcinoma. Oncotarget.
7:18229–18246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wang B, Tao X, Huang CZ, Liu JF, Ye YB and
Huang AM: Decreased expression of liver-type fatty acid-binding
protein is associated with poor prognosis in hepatocellular
carcinoma. Hepatogastroenterology. 61:1321–1326. 2014.PubMed/NCBI
|
|
105
|
Rinella ME, Lazarus JV, Ratziu V, Francque
SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab
JP, et al: A multisociety Delphi consensus statement on new fatty
liver disease nomenclature. J Hepatol. 79:1542–1556. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
European Association for the Study of the
Liver (EASL); European Association for the Study of Diabetes
(EASD); European Association for the Study of Obesity (EASO):
EASL-EASD-EASO Clinical Practice Guidelines on the management of
metabolic dysfunction-associated steatotic liver disease (MASLD). J
Hepatol. 81:492–542. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Anstee QM, Reeves HL, Kotsiliti E, Govaere
O and Heikenwalder M: From NASH to HCC: Current concepts and future
challenges. Nat Rev Gastroenterol Hepatol. 16:411–428. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Diehl AM and Day C: Cause, pathogenesis,
and treatment of nonalcoholic steatohepatitis. N Engl J Med.
377:2063–2072. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Coilly A, Desterke C, Guettier C, Samuel D
and Chiappini F: FABP4 and MMP9 levels identified as predictive
factors for poor prognosis in patients with nonalcoholic fatty
liver using data mining approaches and gene expression analysis.
Sci Rep. 9:197852019. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Milner KL, van der Poorten D, Xu A,
Bugianesi E, Kench JG, Lam KS, Chisholm DJ and George J: Adipocyte
fatty acid binding protein levels relate to inflammation and
fibrosis in nonalcoholic fatty liver disease. Hepatology.
49:1926–1934. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yang H, Deng Q, Ni T, Liu Y, Lu L, Dai H,
Wang H and Yang W: Targeted inhibition of LPL/FABP4/CPT1 fatty acid
metabolic axis can effectively prevent the progression of
nonalcoholic steatohepatitis to liver cancer. Int J Biol Sci.
17:4207–4222. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Leung CON, Gurung S, Chung KPS, Leung RWH,
Lei MML, Chan MSM, Muliawan GK, Khan SA, Wu XQ, Yu J, et al:
Adipocyte-derived FABP4 promotes metabolism-associated steatotic
liver-induced hepatocellular carcinoma by driving ITGB1-mediated
β-catenin activation. J Clin Invest. 135:e1823222025. View Article : Google Scholar
|
|
113
|
Terzić J, Grivennikov S, Karin E and Karin
M: Inflammation and colon cancer. Gastroenterology.
138:2101–2114.e5. 2010. View Article : Google Scholar
|
|
114
|
Ullman TA and Itzkowitz SH: Intestinal
inflammation and cancer. Gastroenterology. 140:1807–1816. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Praslickova D, Torchia EC, Sugiyama MG,
Magrane EJ, Zwicker BL, Kolodzieyski L and Agellon LB: The ileal
lipid binding protein is required for efficient absorption and
transport of bile acids in the distal portion of the murine small
intestine. PLoS One. 7:e508102012. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Kwon K, Kim M, Jung Y, Yoon MY, Lee JY,
Yoon SS, Rho M, Chung YW and Ryu JH: Intestinal dysbiosis caused by
epithelial Fabp6 gene disruption exacerbates gut inflammatory
disease. Immune Netw. 25:e352025. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Ohmachi T, Inoue H, Mimori K, Tanaka F,
Sasaki A, Kanda T, Fujii H, Yanaga K and Mori M: Fatty acid binding
protein 6 is overexpressed in colorectal cancer. Clin Cancer Res.
12:5090–5095. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhang Y, Zhao X, Deng L, Li X, Wang G, Li
Y and Chen M: High expression of FABP4 and FABP6 in patients with
colorectal cancer. World J Surg Oncol. 17:1712019. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Nimptsch K, Aleksandrova K, Pham TT,
Papadimitriou N, Janke J, Christakoudi S, Heath A, Olsen A,
Tjønneland A, Schulze MB, et al: Prospective and Mendelian
randomization analyses on the association of circulating fatty acid
binding protein 4 (FABP-4) and risk of colorectal cancer. BMC Med.
21:3912023. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Calle EE and Kaaks R: Overweight, obesity
and cancer: Epidemiological evidence and proposed mechanisms. Nat
Rev Cancer. 4:579–591. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Park J, Morley TS, Kim M, Clegg DJ and
Scherer PE: Obesity and cancer-mechanisms underlying tumour
progression and recurrence. Nat Rev Endocrinol. 10:455–465. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Iyengar NM, Gucalp A, Dannenberg AJ and
Hudis CA: Obesity and cancer mechanisms: Tumor microenvironment and
inflammation. J Clin Oncol. 34:4270–4276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Goudswaard LJ, Bell JA, Hughes DA, Corbin
LJ, Walter K, Davey Smith G, Soranzo N, Danesh J, Di Angelantonio
E, Ouwehand WH, et al: Effects of adiposity on the human plasma
proteome: Observational and Mendelian randomisation estimates. Int
J Obes (Lond). 45:2221–2229. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Seo J, Jeong DW, Park JW, Lee KW, Fukuda J
and Chun YS: Fatty-acid-induced FABP5/HIF-1 reprograms lipid
metabolism and enhances the proliferation of liver cancer cells.
Commun Biol. 3:6382020. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ishimura S, Furuhashi M, Watanabe Y,
Hoshina K, Fuseya T, Mita T, Okazaki Y, Koyama M, Tanaka M, Akasaka
H, et al: Circulating levels of fatty acid-binding protein family
and metabolic phenotype in the general population. PLoS One.
8:e813182013. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Xu A, Wang Y, Xu JY, Stejskal D, Tam S,
Zhang J, Wat NM, Wong WK and Lam KS: Adipocyte fatty acid-binding
protein is a plasma biomarker closely associated with obesity and
metabolic syndrome. Clin Chem. 52:405–413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Tso AW, Xu A, Sham PC, Wat NM, Wang Y,
Fong CH, Cheung BM, Janus ED and Lam KS: Serum adipocyte fatty acid
binding protein as a new biomarker predicting the development of
type 2 diabetes: A 10-year prospective study in a Chinese cohort.
Diabetes Care. 30:2667–2672. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
von Eynatten M, Breitling LP, Roos M,
Baumann M, Rothenbacher D and Brenner H: Circulating adipocyte
fatty acid-binding protein levels and cardiovascular morbidity and
mortality in patients with coronary heart disease: A 10-year
prospective study. Arterioscler Thromb Vasc Biol. 32:2327–2335.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Cabré A, Lázaro I, Girona J, Manzanares
JM, Marimón F, Plana N, Heras M and Masana L: Fatty acid binding
protein 4 is increased in metabolic syndrome and with
thiazolidinedione treatment in diabetic patients. Atherosclerosis.
195:e150–e158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kralisch S and Fasshauer M: Adipocyte
fatty acid binding protein: A novel adipokine involved in the
pathogenesis of metabolic and vascular disease? Diabetologia.
56:10–21. 2013. View Article : Google Scholar
|
|
133
|
Rezar R, Jirak P, Gschwandtner M, Derler
R, Felder TK, Haslinger M, Kopp K, Seelmaier C, Granitz C, Hoppe UC
and Lichtenauer M: Heart-Type Fatty Acid-Binding protein (H-FABP)
and its role as a biomarker in heart failure: What Do We Know So
Far? J Clin Med. 9:1642020. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Vupputuri A, Sekhar S, Krishnan S,
Venugopal K and Natarajan KU: Heart-type fatty acid-binding protein
(H-FABP) as an early diagnostic biomarker in patients with acute
chest pain. Indian Heart J. 67:538–542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
O'Donoghue M, de Lemos JA, Morrow DA,
Murphy SA, Buros JL, Cannon CP and Sabatine MS: Prognostic utility
of heart-type fatty acid binding protein in patients with acute
coronary syndromes. Circulation. 114:550–557. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ho SK, Wu YW, Tseng WK, Leu HB, Yin WH,
Lin TH, Chang KC, Wang JH, Yeh HI, Wu CC and Chen JW: The
prognostic significance of heart-type fatty acid binding protein in
patients with stable coronary heart disease. Sci Rep. 8:144102018.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Doi K, Noiri E and Sugaya T: Urinary
L-type fatty acid-binding protein as a new renal biomarker in
critical care. Curr Opin Crit Care. 16:545–549. 2010.PubMed/NCBI
|
|
138
|
Kamijo-Ikemori A, Sugaya T, Ichikawa D,
Hoshino S, Matsui K, Yokoyama T, Yasuda T, Hirata K and Kimura K:
Urinary liver type fatty acid binding protein in diabetic
nephropathy. Clin Chim Acta. 424:104–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Eguchi A and Iwasa M: The role of elevated
Liver-type fatty acid-binding proteins in liver diseases. Pharm
Res. 38:89–95. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Sulsky R, Magnin DR, Huang Y, Simpkins L,
Taunk P, Patel M, Zhu Y, Stouch TR, Bassolino-Klimas D, Parker R,
et al: Potent and selective biphenyl azole inhibitors of adipocyte
fatty acid binding protein (aFABP). Bioorg Med Chem Lett.
17:3511–3515. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Barf T, Lehmann F, Hammer K, Haile S, Axen
E, Medina C, Uppenberg J, Svensson S, Rondahl L and Lundbäck T:
N-Benzyl-indolo carboxylic acids: Design and synthesis of potent
and selective adipocyte fatty-acid binding protein (A-FABP)
inhibitors. Bioorg Med Chem Lett. 19:1745–1748. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Furuhashi M: Fatty Acid-binding protein 4
in cardiovascular and metabolic diseases. J Atheroscler Thromb.
26:216–232. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Floresta G, Pistarà V, Amata E, Dichiara
M, Marrazzo A, Prezzavento O and Rescifina A: Adipocyte fatty acid
binding protein 4 (FABP4) inhibitors. A comprehensive systematic
review. Eur J Med Chem. 138:854–873. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Lee MY, Li H, Xiao Y, Zhou Z, Xu A and
Vanhoutte PM: Chronic administration of BMS309403 improves
endothelial function in apolipoprotein E-deficient mice and in
cultured human endothelial cells. Br J Pharmacol. 162:1564–1576.
2011. View Article : Google Scholar
|
|
145
|
Lin W, Huang X, Zhang L, Chen D, Wang D,
Peng Q, Xu L, Li J, Liu X, Li K, et al: BMS309403 stimulates
glucose uptake in myotubes through activation of AMP-activated
protein kinase. PLoS One. 7:e445702012. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Yan F, Shen N, Pang JX, Zhao N, Zhang YW,
Bode AM, Al-Kali A, Litzow MR, Li B and Liu SJ: A vicious loop of
fatty acid-binding protein 4 and DNA methyltransferase 1 promotes
acute myeloid leukemia and acts as a therapeutic target. Leukemia.
32:865–873. 2018. View Article : Google Scholar :
|
|
147
|
Yu C, Li X, Qian X, Zhang H, Li X, Wang B,
Li M, Liu Z, Du W, Chen S, et al: Fatty acid uptake mediated by
FABP4 promotes the formation of CD8+T cell senescence through lipid
peroxidation in the adipocyte-rich microenvironment of Ovarian
Cancer. Oncogenesis. 15:92026. View Article : Google Scholar
|
|
148
|
Jiang X, Xiong Y, Yu J, Avellino A, Liu S,
Han X, Wang Z, Shilyansky JS, Curry MA, Hao J, et al: Expression
profiles of FABP4 and FABP5 in breast cancer: Clinical implications
and perspectives. Discov Oncol. 16:3572025. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Stuart T, Butler A, Hoffman P, Hafemeister
C, Papalexi E, Mauck WM III, Hao Y, Stoeckius M, Smibert P and
Satija R: Comprehensive integration of Single-cell data. Cell.
177:1888–1902.e21. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Lewis SM, Asselin-Labat ML, Nguyen Q,
Berthelet J, Tan X, Wimmer VC, Merino D, Rogers KL and Naik SH:
Spatial omics and multiplexed imaging to explore cancer biology.
Nat Methods. 18:997–1012. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Moses L and Pachter L: Museum of spatial
transcriptomics. Nat Methods. 19:534–546. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Jerby-Arnon L and Regev A: DIALOGUE maps
multicellular programs in tissue from single-cell or spatial
transcriptomics data. Nat Biotechnol. 40:1467–1477. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Nowowiejska J, Baran A and Flisiak I:
Fatty Acid-binding proteins in psoriasis-A review. Metabolites.
12:8332022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Ridaura VK, Faith JJ, Rey FE, Cheng J,
Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, et
al: Gut microbiota from twins discordant for obesity modulate
metabolism in mice. Science. 341:12412142013. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Chang PV: Chemical mechanisms of
colonization resistance by the gut microbial metabolome. ACS Chem
Biol. 15:1119–1126. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Schroeder BO and Bäckhed F: Signals from
the gut microbiota to distant organs in physiology and disease. Nat
Med. 22:1079–1089. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Hang S, Paik D, Yao L, Kim E, Trinath J,
Lu J, Ha S, Nelson BN, Kelly SP, Wu L, et al: Bile acid metabolites
control T(H)17 and T(reg) cell differentiation. Nature.
576:143–148. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Jumper J, Evans R, Pritzel A, Green T,
Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A,
Potapenko A, et al: Highly accurate protein structure prediction
with AlphaFold. Nature. 596:583–589. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Abramson J, Adler J, Dunger J, Evans R,
Green T, Pritzel A, Ronneberger O, Willmore L, Ballard AJ, Bambrick
J, et al: Accurate structure prediction of biomolecular
interactions with AlphaFold 3. Nature. 630:493–500. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Gu S, Shen C, Zhang X, Sun H, Cai H, Luo
H, Zhao H, Liu B, Du H, Zhao Y, et al: Benchmarking AI-powered
docking methods from the perspective of virtual screening. Nat Mach
Intell. 7:509–520. 2025. View Article : Google Scholar
|
|
161
|
Nam KH: Evaluation of AlphaFold3 for the
fatty acids docking to human fatty acid-binding proteins. J Mol
Graph Model. 133:1088722024. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Békés M, Langley DR and Crews CM: PROTAC
targeted protein degraders: The past is prologue. Nat Rev Drug
Discov. 21:181–200. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Burslem GM and Crews CM:
Proteolysis-targeting chimeras as therapeutics and tools for
biological discovery. Cell. 181:102–114. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Mitchell MJ, Billingsley MM, Haley RM,
Wechsler ME, Peppas NA and Langer R: Engineering precision
nanoparticles for drug delivery. Nat Rev Drug Discov. 20:101–124.
2021. View Article : Google Scholar
|
|
165
|
Tsuchikama K and An Z: Antibody-drug
conjugates: Recent advances in conjugation and linker chemistries.
Protein Cell. 9:33–46. 2018. View Article : Google Scholar :
|
|
166
|
Yu J, Hao J, Yorek MS, Jiang X, Avellino
A, Liu S, Han X, Shilyansky J, Wang Z, Wang Y, et al: FABP5 in skin
macrophages mediates saturated fat-induced IL-1β signaling in
psoriatic inflammation. Cell Rep. 44:1162542025. View Article : Google Scholar
|
|
167
|
Zhang Y, Hao J, Zeng J, Li Q, Rao E, Sun
Y, Liu L, Mandal A, Landers VD, Morris RJ, et al: Epidermal FABP
prevents Chemical-Induced skin tumorigenesis by regulation of
TPA-Induced IFN/p53/SOX2 pathway in keratinocytes. J Invest
Dermatol. 138:1925–1934. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Lv J, Hu Y, Li L, He Y, Wang J, Guo N,
Fang Y, Chen Q, Cai C, Tong J, et al: Targeting FABP4 in elderly
mice rejuvenates liver metabolism and ameliorates aging-associated
metabolic disorders. Metabolism. 142:1555282023. View Article : Google Scholar : PubMed/NCBI
|
